Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription Articles published in PLoS Med Retrieve available abstracts of 57 articles: HTML format

Single Articles

June 2024
1. PEREZ CHACON G, Estcourt MJ, Totterdell J, Marsh JA, et al
   Immunogenicity, reactogenicity, and IgE-mediated immune responses of a mixed whole-cell and acellular pertussis vaccine schedule in Australian infants: A randomised, double-blind, noninferiority trial.
   PLoS Med. 2024;21:e1004414.
   PubMed     Abstract available
   
   
   
2. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
   Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules.
   PLoS Med. 2024;21:e1004375.
   PubMed     Abstract available
   
   
   April 2024
3. JUNG SM, Loo SL, Howerton E, Contamin L, et al
   Potential impact of annual vaccination with reformulated COVID-19 vaccines: Lessons from the US COVID-19 scenario modeling hub.
   PLoS Med. 2024;21:e1004387.
   PubMed     Abstract available
   
   
   March 2024
4. MOODIE Z, Andersen-Nissen E, Grunenberg N, Dintwe OB, et al
   Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.
   PLoS Med. 2024;21:e1004360.
   PubMed     Abstract available
   
   
   February 2024
5. NICKEL NC, Phillips-Beck W, Enns JE, Ekuma O, et al
   COVID-19 diagnostic testing and vaccinations among First Nations in Manitoba: A nations-based retrospective cohort study using linked administrative data, 2020-2021.
   PLoS Med. 2024;21:e1004348.
   PubMed     Abstract available
   
   
   January 2024
6. GHARPURE R, Chard AN, Cabrera Escobar M, Zhou W, et al
   Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022.
   PLoS Med. 2024;21:e1004333.
   PubMed     Abstract available
   
   
   November 2023
7. HOGAN AB, Wu SL, Toor J, Olivera Mesa D, et al
   Long-term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: A modelling study.
   PLoS Med. 2023;20:e1004195.
   PubMed     Abstract available
   
   
   
8. BRENNHOFER SA, Platts-Mills JA, Lewnard JA, Liu J, et al
   Burden of diarrhea and antibiotic use among children in low-resource settings preventable by Shigella vaccination: A simulation study.
   PLoS Med. 2023;20:e1004271.
   PubMed     Abstract available
   
   
   September 2023
9. WATKINSON RE, Williams R, Gillibrand S, Munford L, et al
   Evaluating socioeconomic inequalities in influenza vaccine uptake during the COVID-19 pandemic: A cohort study in Greater Manchester, England.
   PLoS Med. 2023;20:e1004289.
   PubMed     Abstract available
   
   
   July 2023
10. XIONG X, Lui DTW, Chung MSH, Au ICH, et al
    Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
    PLoS Med. 2023;20:e1004274.
    PubMed     Abstract available
    
    
    
11. PORTNOY A, Arcand JL, Clark RA, Weerasuriya CK, et al
    The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries: A modeling study.
    PLoS Med. 2023;20:e1004252.
    PubMed     Abstract available
    
    
    June 2023
12. STOWE J, Miller E, Andrews N, Whitaker HJ, et al
    Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
    PLoS Med. 2023;20:e1004245.
    PubMed     Abstract available
    
    
    
13. QIN K, Honjo K, Sherrill-Mix S, Liu W, et al
    Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: A prospective cohort study.
    PLoS Med. 2023;20:e1004157.
    PubMed     Abstract available
    
    
    May 2023
14. KUMAR CK, Sands K, Walsh TR, O'Brien S, et al
    Global, regional, and national estimates of the impact of a maternal Klebsiella pneumoniae vaccine: A Bayesian modeling analysis.
    PLoS Med. 2023;20:e1004239.
    PubMed     Abstract available
    
    
    March 2023
15. MEMIRIE ST, Tolla MT, Rumpler E, Sato R, et al
    Out-of-pocket expenditures and financial risks associated with treatment of vaccine-preventable diseases in Ethiopia: A cross-sectional costing analysis.
    PLoS Med. 2023;20:e1004198.
    PubMed     Abstract available
    
    
    February 2023
16. NORDSTROM P, Ballin M, Nordstrom A
    Safety and effectiveness of monovalent COVID-19 mRNA vaccination and risk factors for hospitalisation caused by the omicron variant in 0.8 million adolescents: A nationwide cohort study in Sweden.
    PLoS Med. 2023;20:e1004127.
    PubMed     Abstract available
    
    
    January 2023
17. DIMITROVA A, Carrasco-Escobar G, Richardson R, Benmarhnia T, et al
    Essential childhood immunization in 43 low- and middle-income countries: Analysis of spatial trends and socioeconomic inequalities in vaccine coverage.
    PLoS Med. 2023;20:e1004166.
    PubMed     Abstract available
    
    
    
18. WAN J, Cazer CL, Clarkberg ME, Henderson SG, et al
    Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study.
    PLoS Med. 2023;20:e1004153.
    PubMed     Abstract available
    
    
    
19. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Correction: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2023;20:e1004159.
    PubMed     Abstract available
    
    
    
20. PORTNOY A, Clark RA, Quaife M, Weerasuriya CK, et al
    The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study.
    PLoS Med. 2023;20:e1004155.
    PubMed     Abstract available
    
    
    
21. BOR J, Assoumou SA, Lane K, Diaz Y, et al
    Inequities in COVID-19 vaccine and booster coverage across Massachusetts ZIP codes after the emergence of Omicron: A population-based cross-sectional study.
    PLoS Med. 2023;20:e1004167.
    PubMed     Abstract available
    
    
    
22. CERQUEIRA-SILVA T, Shah SA, Robertson C, Sanchez M, et al
    Effectiveness of mRNA boosters after homologous primary series with BNT162b2 or ChAdOx1 against symptomatic infection and severe COVID-19 in Brazil and Scotland: A test-negative design case-control study.
    PLoS Med. 2023;20:e1004156.
    PubMed     Abstract available
    
    
    December 2022
23. LIND ML, Robertson AJ, Silva J, Warner F, et al
    Association between primary or booster COVID-19 mRNA vaccination and Omicron lineage BA.1 SARS-CoV-2 infection in people with a prior SARS-CoV-2 infection: A test-negative case-control analysis.
    PLoS Med. 2022;19:e1004136.
    PubMed     Abstract available
    
    
    November 2022
24. BABOUEE FLURY B, Gusewell S, Egger T, Leal O, et al
    Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    PLoS Med. 2022;19:e1004125.
    PubMed     Abstract available
    
    
    
25. NIELSEN KF, Moustsen-Helms IR, Schelde AB, Gram MA, et al
    Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
    PLoS Med. 2022;19:e1004037.
    PubMed     Abstract available
    
    
    October 2022
26. HENSLEY KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, et al
    Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
    PLoS Med. 2022;19:e1003979.
    PubMed     Abstract available
    
    
    September 2022
27. GRAM MA, Emborg HD, Schelde AB, Friis NU, et al
    Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
    PLoS Med. 2022;19:e1003992.
    PubMed     Abstract available
    
    
    August 2022
28. MODY A, Bradley C, Redkar S, Fox B, et al
    Quantifying inequities in COVID-19 vaccine distribution over time by social vulnerability, race and ethnicity, and location: A population-level analysis in St. Louis and Kansas City, Missouri.
    PLoS Med. 2022;19:e1004048.
    PubMed     Abstract available
    
    
    July 2022
29. HERNANDEZ I, Dickson S, Tang S, Gabriel N, et al
    Disparities in distribution of COVID-19 vaccines across US counties: A geographic information system-based cross-sectional study.
    PLoS Med. 2022;19:e1004069.
    PubMed     Abstract available
    
    
    
30. MASSARI M, Spila Alegiani S, Morciano C, Spuri M, et al
    Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study.
    PLoS Med. 2022;19:e1004056.
    PubMed     Abstract available
    
    
    June 2022
31. TAKUVA S, Takalani A, Seocharan I, Yende-Zuma N, et al
    Safety evaluation of the single-dose Ad26.COV2.S vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial.
    PLoS Med. 2022;19:e1004024.
    PubMed     Abstract available
    
    
    
32. WONG CKH, Lau KTK, Xiong X, Au ICH, et al
    Adverse events of special interest and mortality following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines in Hong Kong: A retrospective study.
    PLoS Med. 2022;19:e1004018.
    PubMed     Abstract available
    
    
    May 2022
33. JIN P, Guo X, Chen W, Ma S, et al
    Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    PLoS Med. 2022;19:e1003953.
    PubMed     Abstract available
    
    
    
34. MARTIN CA, Pan D, Melbourne C, Teece L, et al
    Risk factors associated with SARS-CoV-2 infection in a multiethnic cohort of United Kingdom healthcare workers (UK-REACH): A cross-sectional analysis.
    PLoS Med. 2022;19:e1004015.
    PubMed     Abstract available
    
    
    
35. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    Correction: COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2022;19:e1003990.
    PubMed     Abstract available
    
    
    
36. VAN GILS MJ, Lavell A, van der Straten K, Appelman B, et al
    Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study.
    PLoS Med. 2022;19:e1003991.
    PubMed     Abstract available
    
    
    
37. QIAN G, Toizumi M, Clifford S, Le LT, et al
    Association of pneumococcal carriage in infants with the risk of carriage among their contacts in Nha Trang, Vietnam: A nested cross-sectional survey.
    PLoS Med. 2022;19:e1004016.
    PubMed     Abstract available
    
    
    April 2022
38. FOO D, Sarna M, Pereira G, Moore HC, et al
    Prenatal influenza vaccination and allergic and autoimmune diseases in childhood: A longitudinal, population-based linked cohort study.
    PLoS Med. 2022;19:e1003963.
    PubMed     Abstract available
    
    
    
39. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Correction: Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003982.
    PubMed     Abstract available
    
    
    March 2022
40. WATKINSON RE, Williams R, Gillibrand S, Sanders C, et al
    Ethnic inequalities in COVID-19 vaccine uptake and comparison to seasonal influenza vaccine uptake in Greater Manchester, UK: A cohort study.
    PLoS Med. 2022;19:e1003932.
    PubMed     Abstract available
    
    
    February 2022
41. SAAKSVUORI L, Betsch C, Nohynek H, Salo H, et al
    Information nudges for influenza vaccination: Evidence from a large-scale cluster-randomized controlled trial in Finland.
    PLoS Med. 2022;19:e1003919.
    PubMed     Abstract available
    
    
    
42. 
    Vaccine equity: A fundamental imperative in the fight against COVID-19.
    PLoS Med. 2022;19:e1003948.
    PubMed    
    
    
    
43. KERR S, Joy M, Torabi F, Bedston S, et al
    First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: A pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales.
    PLoS Med. 2022;19:e1003927.
    PubMed     Abstract available
    
    
    
44. WHITELEY WN, Ip S, Cooper JA, Bolton T, et al
    Association of COVID-19 vaccines ChAdOx1 and BNT162b2 with major venous, arterial, or thrombocytopenic events: A population-based cohort study of 46 million adults in England.
    PLoS Med. 2022;19:e1003926.
    PubMed     Abstract available
    
    
    
45. MCQUAID F, Mulholland R, Sangpang Rai Y, Agrawal U, et al
    Uptake of infant and preschool immunisations in Scotland and England during the COVID-19 pandemic: An observational study of routinely collected data.
    PLoS Med. 2022;19:e1003916.
    PubMed     Abstract available
    
    
    January 2022
46. GENTILE I, Schiano Moriello N
    COVID-19 prophylaxis in immunosuppressed patients: Beyond vaccination.
    PLoS Med. 2022;19:e1003917.
    PubMed     Abstract available
    
    
    
47. ANYWAINE Z, Barry H, Anzala O, Mutua G, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
    PLoS Med. 2022;19:e1003865.
    PubMed     Abstract available
    
    
    December 2021
48. GRAM MA, Nielsen J, Schelde AB, Nielsen KF, et al
    Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
    PLoS Med. 2021;18:e1003874.
    PubMed     Abstract available
    
    
    
49. PETERSEN M, Schwab J, Havlir DV
    SARS-CoV-2 vaccine boosters: The time to act is now.
    PLoS Med. 2021;18:e1003882.
    PubMed     Abstract available
    
    
    November 2021
50. MARTIN CA, Marshall C, Patel P, Goss C, et al
    SARS-CoV-2 vaccine uptake in a multi-ethnic UK healthcare workforce: A cross-sectional study.
    PLoS Med. 2021;18:e1003823.
    PubMed     Abstract available
    
    
    
51. BHANU C, Gopal DP, Walters K, Chaudhry UAR, et al
    Vaccination uptake amongst older adults from minority ethnic backgrounds: A systematic review.
    PLoS Med. 2021;18:e1003826.
    PubMed     Abstract available
    
    
    October 2021
52. PEARSON CAB, Bozzani F, Procter SR, Davies NG, et al
    COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness.
    PLoS Med. 2021;18:e1003815.
    PubMed     Abstract available
    
    
    
53. FORMICA N, Mallory R, Albert G, Robinson M, et al
    Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
    PLoS Med. 2021;18:e1003769.
    PubMed     Abstract available
    
    
    
54. ISANAKA S, Garba S, Plikaytis B, McNeal MM, et al
    Correction: Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial.
    PLoS Med. 2021;18:e1003776.
    PubMed     Abstract available
    
    
    
55. BARRY H, Mutua G, Kibuuka H, Anywaine Z, et al
    Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa.
    PLoS Med. 2021;18:e1003813.
    PubMed     Abstract available
    
    
    
56. GENG EH, Reid MJA, Goosby E, Abdool-Karim Q, et al
    COVID-19 and global equity for health: The good, the bad, and the wicked.
    PLoS Med. 2021;18:e1003797.
    PubMed     Abstract available
    
    
    September 2021
57. NAGATA JM, Epstein A, Ganson KT, Benmarhnia T, et al
    Drought and child vaccination coverage in 22 countries in sub-Saharan Africa: A retrospective analysis of national survey data from 2011 to 2019.
    PLoS Med. 2021;18:e1003678.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.